Avience Biomedicals IPO Allotment Status: How to Check via Skyline Financial, NSE Portal or Broker

Investors who applied for the Avience Biomedicals IPO will be able to check their allotment status on the official NSE SME IPO allotment portal or through the registrar Skyline Financial Services Private Limited once the basis of allotment is finalised. The Avience Biomedicals IPO is a Rs 30.24 crore 100% fresh issue at a price band of Rs 196 to Rs 208 per share, proposing to list on the NSE SME platform. With the grey market premium running at Rs 85 on Day 3 of GMP tracking, allottees are positioned to potentially receive allotment at a significant discount to the expected listing price of approximately Rs 293. Kunal Singla, Associate Director at Univest, recommends that Avience Biomedicals IPO allottees plan their post-allotment strategy carefully, noting that while the GMP of Rs 85 is encouraging, actual listing prices on the NSE SME platform can deviate significantly from GMP-implied levels, particularly for smaller issues where sell-on-listing volumes can overwhelm initial buy interest.
Click Here – Get Free Investment Predictions

Avience Biomedicals IPO Allotment: Key Details

Avience Biomedicals IPO Allotment Details	Information
Issue Type	Book-Built Issue | NSE SME Platform
Price Band	Rs 196 to Rs 208 per share (face value Rs 10)
Issue Size	Rs 30.24 crore | 100% Fresh Issue | 14,53,800 equity shares
Allotment Status Check	NSE IPO portal | Skyline Financial Services (registrar) | Broker’s app
Allotment Basis	Proportionate for NII; Lottery for retail if oversubscribed
GMP at Allotment	Rs 85 (+40.9% premium) | Implied listing ~Rs 293 (unofficial, not guaranteed)
Listing Exchange	NSE SME Platform
Registrar	Skyline Financial Services Private Limited
Refund (non-allottees)	Blocked amounts refunded via UPI/ASBA post allotment finalisation
Demat Credit (allottees)	Shares credited before listing
FY25 Revenue / PAT	Rs 45.97 crore (+88.6% YoY) / Rs 7.23 crore (+237.9% YoY)

How to Check Avience Biomedicals IPO Allotment Status

Method 1: Skyline Financial Services Registrar Portal

Skyline Financial Services Private Limited is the official registrar for the Avience Biomedicals IPO. Investors can check the Avience Biomedicals IPO allotment status directly on the Skyline Financial Services website. Visit the website, select the “Avience Biomedicals Limited” IPO from the dropdown menu, enter your PAN number, Application Number or DP and Client ID, and submit to view your Avience Biomedicals IPO allotment status.

Method 2: NSE SME IPO Allotment Portal

The Avience Biomedicals IPO allotment can also be checked through the official NSE website. Navigate to the IPO section at www.nseindia.com, select “Avience Biomedicals Limited” and enter your PAN or Application Number. The NSE IPO allotment status page is updated after the basis of allotment is finalised and is available for all NSE-listed issues including NSE SME IPOs.

Method 3: Broker Platforms

All major SEBI-registered stockbrokers display IPO allotment status in their platforms. Log in to your broker account (Zerodha, Groww, Angel One, HDFC Securities, Upstox etc.) and navigate to the IPO section to check your Avience Biomedicals IPO allotment status. If allotted, the shares will appear in your holdings section with the allotment price of Rs 208 (upper band).

What Happens After Avience Biomedicals IPO Allotment

If You Receive Avience Biomedicals IPO Allotment

Avience Biomedicals IPO allottees will receive equity shares credited to their demat account at the IPO issue price of Rs 208 (upper band) before the listing date on NSE SME. The GMP of Rs 85 implies a potential listing near Rs 293, which would represent a gain of approximately 40.9% on the Rs 208 issue price. However, allottees should not take listing gains for granted: actual listing performance depends on overall market conditions, SME IPO sentiment and the volume of sell-on-listing orders relative to buy interest. Kunal Singla recommends that allottees set a pre-determined sell target or stop-loss before listing rather than making emotional decisions based on intraday price movements.

If You Do Not Receive Avience Biomedicals IPO Allotment

Non-allottees of the Avience Biomedicals IPO will have their blocked amounts automatically released through the ASBA or UPI unblocking mechanism after the basis of allotment is finalised. The funds will be available in the bank account within the SEBI-mandated timeline. Investors who missed the allotment but remain interested in Avience Biomedicals can track the listing day performance and consider a secondary market purchase if the listing price corrects from the GMP-implied level to a more attractive entry point.

Explore IPO and Stock Research on the Univest Screener

Hold vs Sell Strategy for Avience Biomedicals IPO Allottees

The Avience Biomedicals IPO allotment decision on whether to hold or sell on listing depends on individual financial goals. If the stock lists near Rs 293 (GMP-implied), allottees are looking at a 40.9% gain on the issue price. For investors with high risk tolerance, Avience Biomedicals’s diagnostics business, Mindray channel partnership and YEIDA Medical Device Park expansion could support a longer-term hold thesis. For risk-averse investors, a listing-day exit near the GMP-implied level locks in gains and avoids exposure to SME post-listing volatility. The nil GMP reversal or decline from Rs 85 would signal selling pressure and warrant caution. Consult a SEBI-registered financial advisor.

Conclusion

The Avience Biomedicals IPO allotment will be finalised after the subscription window closes. Check allotment status via Skyline Financial Services (registrar), NSE IPO allotment portal or your broker’s platform using PAN or application number. The GMP of Rs 85 implies a potential listing near Rs 293 (+40.9% over Rs 208). Allottees should plan listing strategy based on fundamentals and risk appetite. Consult a SEBI-registered financial advisor before investing.

Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Please read all scheme-related documents carefully before investing. Univest (Uniresearch Global Pvt Ltd) is a SEBI-registered Research Analyst (INH000013776). Past performance is not indicative of future returns.

Frequently Asked Questions

How do I check Avience Biomedicals IPO allotment status?

Ans. To check the Avience Biomedicals IPO allotment status, visit the Skyline Financial Services Private Limited website (the official registrar), select Avience Biomedicals Limited from the IPO dropdown and enter your PAN number or Application Number. You can also check via the NSE IPO allotment status page at www.nseindia.com or through your broker’s platform. Allotment status becomes available after the basis of allotment is finalised.

What is the GMP for Avience Biomedicals IPO at allotment?

Ans. The Avience Biomedicals IPO grey market premium stands at Rs 85 on Day 3 of GMP tracking, implying a potential listing price of approximately Rs 293 per share, a premium of approximately 40.9% over the upper issue price of Rs 208. This is an unofficial, unregulated indicator and actual listing price may differ significantly. The GMP has been on an upward trajectory from Rs 40 to Rs 70 to Rs 85, indicating growing grey market demand.

What will the Avience Biomedicals IPO listing price be?

Ans. Based on the current grey market premium of Rs 85, the Avience Biomedicals IPO is expected to list at approximately Rs 293 per share on the NSE SME platform, representing a premium of approximately 40.9% above the Rs 208 upper issue price. However, GMP is not a reliable predictor of actual listing prices, particularly for SME IPOs where lower liquidity can create significant price volatility on the listing day.

Who is the registrar for Avience Biomedicals IPO allotment?

Ans. Skyline Financial Services Private Limited is the official registrar to the Avience Biomedicals IPO. Investors can check the Avience Biomedicals IPO allotment status on the Skyline Financial Services website by entering their PAN number, Application Number or DP and Client ID. The registrar processes the allotment basis, manages the demat credit to allottees and coordinates the ASBA and UPI refund for non-allottees.

Should this Avience IPO allottees hold or sell on listing?

Ans. Whether to hold or sell Avience Biomedicals shares on listing depends on the actual listing price, market conditions and individual investment goals. If the stock lists near Rs 293 as implied by the Rs 85 GMP, allottees are sitting on a 40.9% gain. For long-term investors, Avience Biomedicals’s diagnostics business and YEIDA manufacturing expansion could support a hold thesis. For risk-averse investors, a listing-day exit locks in gains. Consult a SEBI-registered financial advisor before deciding.

What happens to my blocked amount if I don’t get this Avience IPO allotment?

Ans. If you do not receive allotment in the Avience Biomedicals IPO, the amount blocked in your bank account through ASBA will be automatically unblocked after the basis of allotment is finalised. For UPI-based applications, the mandate block will be cancelled. The funds will be released within the SEBI-mandated timeline. No separate refund application is needed, as the ASBA and UPI mechanisms handle this automatically.

What is Avience Biomedicals’ business?

Ans. Avience Biomedicals Limited is a Noida-based molecular diagnostics and medical device manufacturer. Products include IVD rapid test kits for COVID-19, HIV, malaria, dengue and HBsAg, serology products, biochemistry analysers, haematology analysers and Viral Transport Media. The company is a Mindray channel partner and serves pathology labs, hospitals, research centres and government bodies through B2B and B2G channels. Net proceeds will be used for a new manufacturing facility at YEIDA Medical Device Park.

What are the risks for Avience Biomedicals IPO allottees?

Ans. Key risks for Avience Biomedicals IPO allottees include: the stock is on the NSE SME platform with lower post-listing liquidity; customer concentration with top 10 customers contributing 56.82% of FY25 revenues; sustainability of FY25 high growth rates not guaranteed; outstanding borrowings of Rs 26.73 crore; and potential gap between GMP-implied listing price and actual listing price in a low-liquidity SME environment. Consult a SEBI-registered financial advisor before making post-allotment decisions.